PharmaEssentia reports two-year Phase 3 SURPASS-ET data for BESREMi in high-risk essential thrombocythemia

• PharmaEssentia will present two posters at the SOHO 2026 meeting on Sept. 9-12 in Houston.
• Two-year Phase 3 SURPASS-ET extension results were partly presented earlier at EHA 2026.
• Patients staying on BESREMi in high-risk essential thrombocythemia sustained clinical responses, kept blood counts controlled, showed continued molecular improvement.
• Patients switching from anagrelide to BESREMi showed better blood-count control with a more favorable molecular profile than on prior therapy.
• A US community-oncology study suggested BESREMi use often followed first-line therapy, with response trends broadly consistent across prior treatment histories.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202609090842BIZWIRE_USPR_____20260909_BW431641) on September 09, 2026, and is solely responsible for the information contained therein.